Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

NCT ID: NCT03265808

Last Updated: 2026-01-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-03-18
• Study Completion Date: 2025-07-30

Brief Summary

The purpose of this study is to look at the safety of a study treatment with stem cells in Alcohol Use Disorder And Major Depression (AUD-MD) subjects.

Detailed Description

This is a randomized, double-blind placebo-controlled study of allogeneic human mesenchymal stem cell in subjects with comorbid Alcohol Use Disorder And Major Depression (AUD-MD). 80 subjects will be randomized (1:1) to active treatment vs. placebo an followed weekly for 12 weeks and then every 3 months for 12 months.

Conditions

Major Depressive Disorder; Alcohol Use Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

allogeneic human mesenchymal stem cells (allo-hMSCs)

Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10\^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.

Group Type: EXPERIMENTAL

allogeneic human mesenchymal stem cells (allo-hMSCs)

Intervention Type: DRUG

Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.

Placebo

Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.

Interventions

allogeneic human mesenchymal stem cells (allo-hMSCs)

Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.

Intervention Type: DRUG

Placebo

Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Provide written informed consent.

2. Subjects age >18 and <75 years at the time of signing the Informed Consent Form.

3. Diagnostic and Statistical Manual of Mental Disorder-5 criteria for Alcohol Urge Questionnaire (moderate or severe defined as meeting 4 or more of the 11 criteria) AND a concurrent Diagnostic and Statistical Manual of Mental Disorder-5 recurrent unipolar major depression with HRSD-25 score of 18 or above.

4. A history of a depressive episode occurring or persisting during a period of one-month abstinence.

5. Participants should express the desire to reduce or stop alcohol consumption, report 28 or more standard drinks (SD) per week for males or 21 for females over four weeks during the 90 days preceding study enrollment.

6. Increased inflammation ([serum C-reactive protein] ≥3.0 mg/L.

7. Agree to taper and discontinue antidepressant medications during the 12-week trial.

8. Able to provide informed consent and comply with study procedures.

9. Able to read English and understand study instruments.

10. Entry criteria for depression and alcohol use disorder (moderate or severe) will be established using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID) for categorical diagnosis.

11. Have a score of ≥18 on the Hamilton Depression Rating Scale for Depression (HAM-D).

Exclusion Criteria

1. Acute suicidality.

2. Any lifetime history of bipolar disorder, schizophrenia, or schizoaffective disorder.

3. Active psychotic disorder, eating disorder, or substance use disorder except for alcohol and tobacco or "mild" cannabis use disorder within 6 months of enrollment.

4. Any lifetime history of autoimmune or immunodeficiency syndrome.

5. Treatment with any psychotropic (including hypnotic), steroidal, or anti-inflammatory medication (including NSAIDs) within 2 weeks of treatment randomization (6 weeks for fluoxetine).

6. Any current use of medication that affect alcohol consumption such as acamprosate, disulfiram, naltrexone (po or IM), topiramate, or sedative-hypnotics including benzodiazepines or any psychostimulant.

7. Being enrolled in an alcohol treatment program (self-help groups participation such as Alcoholics Anonymous or Dual Diagnosis self-help are allowed).

8. Active medical condition that could cause or exacerbate depressive symptoms (e.g., hypothyroidism, anemia).

9. Currently pregnant or breast-feeding.

10. Lack of use of a reliable means of contraception methods. (Female subjects of childbearing potential must undergo a serum or urine pregnancy test at screening and within 36 hours prior to infusion.)

11. First major depressive episode after 50 years of age.

12. Any evidence of current infection including serum positive for HIV, hepatitis BsAg or Viremic hepatitis.

13. Medical conditions with known autoimmune or inflammatory mechanisms including any chronic allergic condition.

14. Positive urine screens for any drug of abuse other than cannabis at baseline.

15. Inability to read or understand study forms or informed consent or the presence of any other conditions or factors, which in the opinion of the investigator would make the patient unsuitable for study participation.

16. Prior history of a suicide attempt, within the past year.

17. Have hypersensitivity to dimethyl sulfoxide (DMSO).

18. Have a clinical history of malignancy within 3 years (i.e., subjects with prior malignancy must be disease free for 3 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma.

19. Be serum positive for HIV, hepatitis BsAg or Viremic hepatitis C.

20. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

Sponsor Role: collaborator

Ihsan M Salloum, MD, MPH

OTHER

Sponsor Role: lead

Responsible Party

Ihsan M Salloum, MD, MPH

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Ihsan Salloum, MD

Role: PRINCIPAL_INVESTIGATOR

University of Texas Rio Grande Valley School of Medicine

Locations

University of Texas Rio Grande Valley School of Medicine

Harlingen, Texas, United States

Countries

United States

Other Identifiers

1R01AA024933-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

20170674

Identifier Type: -

Identifier Source: org_study_id